Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease

Table 1 Baseline characteristics of the linezolid and control groups*

Variable	Linezolid group	Control group	P value
Number	164	172
Age, years	54.6 ± 11.9	57.0 ± 14.7	0.153
Gender, female	112 (68.3)	104 (60.5)	0.134
BMI, kg/m²	17.4 ± 5.0	18.5 ± 5.7	0.158
NTM-PD, retreatment	64 (39.0)	60 (34.9)	0.432
Previous pulmonary TB	34 (20.7)	42 (24.4)	0.419
Comorbidity
COPD	12 (7.3)	18 (10.5)	0.312
Diabetes Mellitus	8 (4.9)	6 (3.5)	0.524
Immunosuppressed	6 (3.7)	9 (5.2)	0.485
Respiratory symptoms
Cough	122 (74.4)	139 (80.8)	0.158
Expectoration	122 (74.4)	139 (80.8)	0.158
Hemoptysis	66 (40.2)	80 (46.5)	0.247
Fever	25 (15.2)	30 (17.4)	0.586
Dyspnea	24 (14.6)	27 (15.7)	0.786
Chest CT findings
Nodular bronchiectatic	119 (72.6)	134 (77.9)	0.256
Fibrocavitary	58 (35.3)	49 (28.5)	0.176
Other	6 (3.7)	8 (4.7)	0.649

*Numbers indicate n (%) or mean ± SD
BMI: body mass index; NTM-PD: nontuberculous mycobacterial pulmonary disease; TB: tuberculous; COPD: chronic obstructive pulmonary disease

ISSN: 1476-0711